高级检索
当前位置: 首页 > 详情页

Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence.

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China [2]Beijing Institute of Basic Medical Sciences, Beijing, China [3]Department of Pathology, TheSecond Affiliated Hospital of Shandong First Medical University, Taian, China [4]Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases ofWomen and Children of Ministry of Education, West China Second Hospital and State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China Hospital, SichuanUniversity, Chengdu, China [5]Department of Pathology, Taian Tumor Prevention and Treatment Hospital, Taian, China [6]Department of Biostatistics, School of Public Health,Shandong University, Jinan, China [7]Key Laboratory of Biochip Technology, Shenzhen Research Institute, City University of Hong Kong, Shenzhen, China
出处:
ISSN:

摘要:
Epithelial ovarian cancers (EOCs) are sensitive to chemotherapy but will ultimately relapse and develop drug resistance. The origin of EOC recurrence has been elusive due to intra-tumor heterogeneity. Here we performed single-cell RNA sequencing (scRNA-seq) in 13,369 cells from primary, untreated peritoneal metastasis, and relapse tumors. We used time-resolved analysis to chart the developmental sequence of cells from the metastatic tumors, then traced the earliest replanting cells back to the primary tumors. We discovered seven distinct subpopulations in primary tumors where the CYR61+ "stress" subpopulation was identified as the relapse-initiators. Furthermore, a subpopulation of RGS5+ cancer-associated fibroblasts (CAFs) was found to strongly support tumor metastasis. The combined CYR61/RGS5 expression scores significantly correlated with the relapse-free-survival of EOC patients and can be used as predictors of EOC recurrence. Our study provides insights into the mechanism of EOC recurrence and presents CYR61+ relapse-initiating cells as potential therapeutic targets to prevent EOC relapse.© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 1 区 医学
小类 | 1 区 遗传学 1 区 生化与分子生物学 1 区 肿瘤学 2 区 细胞生物学
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 生化与分子生物学 1 区 遗传学 2 区 细胞生物学 2 区 肿瘤学
第一作者:
第一作者机构: [1]Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China [2]Beijing Institute of Basic Medical Sciences, Beijing, China
通讯作者:
通讯机构: [1]Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China [2]Beijing Institute of Basic Medical Sciences, Beijing, China [7]Key Laboratory of Biochip Technology, Shenzhen Research Institute, City University of Hong Kong, Shenzhen, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43389 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号